Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled
Merck & Co. is a global healthcare company organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease, cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in H1 2025nasdaq.com. Other pillars include GARDASIL® and type-2 diabetes drugs. Merck invests heavily in R&D, with hundreds of projects in clinical development. In mid-2025 the company announced a transformation plan to reallocate resources toward “new growth drivers” – including acquisitions and upcoming product launches – to drive long-term innovationmerck.com.
